Previous 10 | Next 10 |
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 161,901,639 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 91,101,164 shares Biodexa Pharmaceuticals plc (BDRX) rose 88.6% to $1.62 on volume of 87,7...
2024-03-28 13:01:46 ET More on Mid-day movers & stocks. System1, Inc. (SST) Q4 2023 Earnings Call Transcript Allego N.V. gains after new partnership with Ford is unveiled Seeking Alpha’s Quant Rating on Allego Historical earnings data for Allego ...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 54.8% to $0.2552 on volume of 35,107,796 shares Nikola Corporation (NKLA) rose 5.0% to $0.9546 on volume of 25,515,019 shares Biodexa Pharmaceuticals plc (BDRX) rose 83.9% to $1.58 on volume of 24,185,655 shar...
2024-03-28 09:20:29 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- This morning’s notable listings with recent news include Treasure & Shipwreck Recovery (OTCPK: BLIS ), Akebia Therapeutics, Inc. (NASDAQ: AKBA ), Avalo Therapeutics, Inc. (NASDAQ: AV...
2024-03-28 07:38:20 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- Avalo Therapeutics, Inc. (NASDAQ: AVTX ) reported, after yesterday’s market close, that it acquired AlmataBio, Inc. and its Phase 2-ready anti-IL-1β mAb. Additionally, Avalo agreed to sell pr...
2024-03-27 16:16:07 ET More on Avalo Therapeutics Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics Read the full article on Seeking Alpha For further...
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront invest...
2023-12-29 13:02:59 ET Gainers: Sentage Holdings ( SNTG ) +262% . China SXT Pharmaceuticals ( SXTC ) +107% . China Green Agriculture ( CGA ) +54% . Aditxt ( ADTX ) +33% . TC BioPharm ( TCBP ) +30% . Bright Health Group ( BH...
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...